1. Generics Bulletin
  2. >>Business
  3. >>Deals

Zydus Buys Stake In Sterling Biotech – Will API Segment Restructuring Accelerate?

PE Interest Has Been Growing

 
• By Vibha Ravi

Does Zydus’ 50% stake acquisition in Sterling Biotech reflect a broader move of formulations companies to secure API supplies or acceleration of API segment restructuring begun by a couple of private equity (PE) funds?

Zydus' Acquisition Of Stake In Sterling Biotech Accelerates Winds Of Change
Zydus' Acquisition Of Stake In Sterling Biotech Accelerates Winds Of Change • Source: Shutterstock

The active pharmaceutical ingredients (API) segment is witnessing a gradual restructuring with an increasing number of large Indian companies expanding their presence via new facilities or stake acquisitions in existing firms.

The latest to join the bandwagon is Zydus Lifesciences Limited, which via subsidiary Zydus Animal Health and Investments Ltd, has acquired a 50% stake in gelatin, dicalcium phosphate and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Abiogen And mAbxience Join Forces In Italy

 
• By Dave Wallace

Spanish biosimilars developer mAbxience has struck a deal with Italy’s Abiogen covering an undisclosed biosimilar for the Italian market.

Teva Brings In European Trastuzumab With Prestige BioPharma Agreement

 
• By Dean Rudge

Teva will now market biosimilar Herceptin in both the US and Europe, after penning an agreement with Singaporean firm Prestige BioPharma for its Tuznue rival to the monoclonal antibody to treat HER2-positive breast cancer and HER2-positive metastatic stomach cancer.

SteinCares Deal Leads Lupin’s Ranibizumab Into Latin America

 
• By Dave Wallace

Lupin is planning to make inroads into the Latin American biosimilars market through a deal with local player SteinCares for a ranibizumab rival to Lucentis.

Advanz Allies With Pharmathen On Long-Acting Injectable

 
• By Dave Wallace

Advanz Pharma has announced details of a fresh alliance on long-acting injectables with Pharmathen.

More from Business

SteinCares Deal Leads Lupin’s Ranibizumab Into Latin America

 
• By Dave Wallace

Lupin is planning to make inroads into the Latin American biosimilars market through a deal with local player SteinCares for a ranibizumab rival to Lucentis.

Hikma Gears Up To Enter US Biosimilars Market With Ustekinumab Nod

 
• By Dave Wallace

Hikma is set to make its first launch into the competitive US biosimilars market after its Bio-Thera-partnered Stelara rival, Starjemza, was approved by the FDA.

Advanz Allies With Pharmathen On Long-Acting Injectable

 
• By Dave Wallace

Advanz Pharma has announced details of a fresh alliance on long-acting injectables with Pharmathen.